While anti-CD20- or CD22- directed CAR T-cell therapy may have a role in the treatment of pediatric patients with R/R ALL who relapse following anti-CD19 CAR T-cell therapy, it is evident that improved CAR constructs may be needed in order to achieve durable remission. Here, CD19 is linked to acute lymphoblastic leukemia.